Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease

Am J Cardiol. 2005 Jan 15;95(2):236-40. doi: 10.1016/j.amjcard.2004.08.093.

Abstract

This study assessed the effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand after percutaneous coronary intervention in patients who had stable coronary artery disease. Tirofiban insignificantly limited the increase of soluble CD40 ligand after revascularization, especially in patients who had high levels of this marker at baseline (p = 0.06), whereas statins significantly inhibited increases in interleukin-6 and, to a lesser extent, high-sensitivity C-reactive protein without affecting the soluble CD40 ligand.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Angioplasty, Balloon, Coronary
  • C-Reactive Protein / metabolism
  • CD40 Ligand / blood
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / therapy
  • Coronary Restenosis / prevention & control*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Infusions, Intravenous
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Prospective Studies
  • Tirofiban
  • Treatment Outcome
  • Tyrosine / administration & dosage*
  • Tyrosine / analogs & derivatives*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Interleukin-6
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • CD40 Ligand
  • Tyrosine
  • C-Reactive Protein
  • Tirofiban